Treatment of Relapsed/Refractory Myeloma (excluding T-cell redirection therapy)
A real-world UK experience of Daratumumab, Velcade, Dexamethasone and Carfilzomib, Lenalidomide, Dexamethasone as second line therapies in the UK: a South East London retrospective
Arief S. Gunawan, MBBS, PhD, FRCPath (he/him/his)
Consultant Haematologist
King's College Hospitals
London, United Kingdom